Centers | ||
|
|
|
UCSC Chemical Screening Center | VMCC, University of Michigan | Therapeutic Accelerator Program (TAP) |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... |
Test |
Partnerships |
Events |
Jobs |
JDRF & Novo Nordisk to Collaborate on Type 1 DiabetesJDRF and Novo Nordisk have entered into collaboration to develop new immunotherapies to treat Type 1 diabetes. The new partnership will be based out of Novo's newly opened Type 1 Diabetes R&D Center in Seattle. JDRF and Novo Nordisk will be... View all Merck Serono and Feinstein Institute to Develop New Drugs to Treat LupusMerck Serono and Feinstein Institute the research arm of North Shore-Long Island Jewish Health System in New York have entered into a joint collaboration to develop new antibody based therapies to treat Systemic Lupus Erythematosus (SLE). Merck... View all Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all |
No EVENTS for listing |
No Job Posts |
